Insmed Forecasts 2025 Revenues of $606 Million Driven by ARIKAYCE and BRINSUPRI

Reuters01-09

<a href="https://laohu8.com/S/INSM">Insmed</a> Forecasts 2025 Revenues of $606 Million Driven by ARIKAYCE and BRINSUPRI

Insmed Inc. has released its preliminary unaudited financial outlook for full-year 2025, projecting total global net product revenues of $606.4 million, a 67% increase compared to $363.7 million in 2024. U.S. revenues are expected to rise sharply to $453.0 million from $254.8 million, marking a 78% increase, while international revenues are forecasted to grow by 41% to $153.5 million. The growth is driven by strong performances from ARIKAYCE, with global revenues anticipated to reach $433.8 million (up 19% year-over-year), and the launch of BRINSUPRI, which is projected to generate $172.7 million in U.S. sales in its first reported year. As of the end of 2025, approximately 4,000 medical professionals have prescribed BRINSUPRI, with around 9,000 new patients initiating therapy in the fourth quarter alone.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Insmed Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY59462) on January 09, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2602378142?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-09 20:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2602378142","market":"nz","top_or_hot":-1,"title":"Insmed Forecasts 2025 Revenues of $606 Million Driven by ARIKAYCE and BRINSUPRI","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/INSM\">Insmed</a> Forecasts 2025 Revenues of $606 Million Driven by ARIKAYCE and BRINSUPRI\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Insmed Inc. has released its preliminary unaudited financial outlook for full-year 2025, projecting total global net product revenues of $606.4 million, a 67% increase compared to $363.7 million in 2024. U.S. revenues are expected to rise sharply to $453.0 million from $254.8 million, marking a 78% increase, while international revenues are forecasted to grow by 41% to $153.5 million. The growth is driven by strong performances from ARIKAYCE, with global revenues anticipated to reach $433.8 million (up 19% year-over-year), and the launch of BRINSUPRI, which is projected to generate $172.7 million in U.S. sales in its first reported year. As of the end of 2025, approximately 4,000 medical professionals have prescribed BRINSUPRI, with around 9,000 new patients initiating therapy in the fourth quarter alone.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Insmed Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY59462) on January 09, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Insmed Forecasts 2025 Revenues of $606 Million Driven by ARIKAYCE and BRINSUPRI</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInsmed Forecasts 2025 Revenues of $606 Million Driven by ARIKAYCE and BRINSUPRI\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-09 20:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/INSM\">Insmed</a> Forecasts 2025 Revenues of $606 Million Driven by ARIKAYCE and BRINSUPRI\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Insmed Inc. has released its preliminary unaudited financial outlook for full-year 2025, projecting total global net product revenues of $606.4 million, a 67% increase compared to $363.7 million in 2024. U.S. revenues are expected to rise sharply to $453.0 million from $254.8 million, marking a 78% increase, while international revenues are forecasted to grow by 41% to $153.5 million. The growth is driven by strong performances from ARIKAYCE, with global revenues anticipated to reach $433.8 million (up 19% year-over-year), and the launch of BRINSUPRI, which is projected to generate $172.7 million in U.S. sales in its first reported year. As of the end of 2025, approximately 4,000 medical professionals have prescribed BRINSUPRI, with around 9,000 new patients initiating therapy in the fourth quarter alone.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Insmed Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY59462) on January 09, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0889565916.HKD","symbol_name":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260109:nNDL1pqlsD:1","article_id":"2602378142","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2602378142","pubTimestamp":1767960077,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Insmed Inc. has released its preliminary unaudited financial outlook for full-year 2025, projecting total global net product revenues of $606.4 million, a 67% increase compared to $363.7 million in 2024. U.S. revenues are expected to rise sharply to $453.0 million from $254.8 million, marking a 78% increase, while international revenues are forecasted to grow by 41% to $153.5 million. The growth is driven by strong performances from ARIKAYCE, with global revenues anticipated to reach $433.8 million , and the launch of BRINSUPRI, which is projected to generate $172.7 million in U.S. sales in its first reported year. As of the end of 2025, approximately 4,000 medical professionals have prescribed BRINSUPRI, with around 9,000 new patients initiating therapy in the fourth quarter alone.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for infor","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","INSM":"Insmed","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","BK4139":"生物科技","LU0053671581.USD":"摩根大通美国小盘成长股 A(dist)","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)"},"translate_title":"Insmed预测2025年收入将在ARIKAYCE和BRINSUPRI的推动下达到6.06亿美元","themeId":"87f58df0cea45f9dc7f6df99dc1f4be0","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INSM":0.9},"content_text":"Insmed Forecasts 2025 Revenues of $606 Million Driven by ARIKAYCE and BRINSUPRI\n    \n\n        Insmed Inc. has released its preliminary unaudited financial outlook for full-year 2025, projecting total global net product revenues of $606.4 million, a 67% increase compared to $363.7 million in 2024. U.S. revenues are expected to rise sharply to $453.0 million from $254.8 million, marking a 78% increase, while international revenues are forecasted to grow by 41% to $153.5 million. The growth is driven by strong performances from ARIKAYCE, with global revenues anticipated to reach $433.8 million (up 19% year-over-year), and the launch of BRINSUPRI, which is projected to generate $172.7 million in U.S. sales in its first reported year. As of the end of 2025, approximately 4,000 medical professionals have prescribed BRINSUPRI, with around 9,000 new patients initiating therapy in the fourth quarter alone.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Insmed Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY59462) on January 09, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2602378142","isCrawlerRequest":true}